PHARMACY POLICY STATEMENT
Marketplace

DRUG NAME	Evkeeza (evinacumab-dgnb)
BENEFIT TYPE	Medical
STATUS	Prior Authorization Required

Evkeeza, approved by the FDA in 2021, is an ANGPTL3 (angiopoietin-like 3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia (HoFH).
Evkeeza is the first ANGPTL3 inhibitor to be approved. ANGPTL3 is a protein in the liver that has a role in regulating lipid metabolism. Its inhibition reduces LDL, HDL, and triglycerides.

Evkeeza (evinacumab-dgnb) will be considered for coverage when the following criteria are met:

Homozygous Familial Hypercholesterolemia (HoFH)

For **initial** authorization:

1. Member is at least 5 years of age; AND
2. Medication must be prescribed by or in consultation with a lipid specialist or cardiologist; AND
3. Member has a diagnosis of homozygous familial hypercholesterolemia (HoFH) confirmed by **one** of the following:
   a) Genetic testing confirmation of two mutant alleles in the *LDLR, Apo-B, PCSK9*, or *LDLRAP1* gene locus; OR
   b) LDL-C > 500 mg/dL before any treatment or LDL-C > 300 mg/dL if treated with a lipid-lowering drug AND **one** of the following:
      i) Cutaneous or tendon xanthoma before 10 years of age; OR
      ii) Untreated elevated LDL-C levels consistent with heterozygous FH in both parents; AND
4. Chart notes must include documentation of baseline LDL-C level above goal within the past 90 days; AND
5. Member is unable to achieve LDL-C goal (see Note below) after trials with **both** of the following:
   a) 90-day trial of a high-intensity statin plus ezetimibe. If intolerance occurs, a second attempt must be initiated with a moderate or low-intensity statin + ezetimibe;
   b) 90-day trial with a PCSK9 inhibitor (e.29 G [Tf 1 0 0 14(o)-14(m)47(o)- f* 48.87 n ET Q q 49.

For **reauthorization**:

1.